Clinico-pathological and treatment-related factors influencing survival in parotid cancer by Renehan, A G et al.
Carcinomas of the parotid gland are relatively uncommon malig-
nancies (0.6 per 105 population; HMSO, 1997). They are
frequently characterized by a long natural history and, conse-
quently, their study is rendered difficult both by the time taken to
accrue sufficient patients for analysis and the fact that at least
10-year follow-up is required to adequately assess treatment
outcome (Spiro, 1986). Prospective randomized trials are usually
impractical in such circumstances. Consensus on treatment can
only be obtained from analysis of large retrospective studies in
which multivariate analysis is the most appropriate method of
evaluation. The purpose of this study is to identify important prog-
nostic and treatment-related factors that influence survival in
parotid cancer. For purposes of comparison, factors critical to
locoregional recurrence and distant metastasis will also be
examined.
PATIENTS AND METHODS
Between 1952 and 1992, a total of 825 patients with previously
untreated parotid neoplasms were surgically treated at the Christie
Hospital, Manchester and previously summarized by the authors
(Renehan et al, 1996). A histological diagnosis of carcinoma was
established in 143 patients (16%), of which 40 patients were
considered incurable at diagnosis and treated palliatively. The
remaining 103 formed the focus of this study. Survival data and
disease status has been evaluated to 1997, such that all survivors
were followed for a minimum of 5 years (median 12, range 5–32).
There were 52 males (median age: 55; range 9–85 years) and
51 females (median age: 62; range 10–92 years). The median dura-
tion of symptoms was 10 (range 1–300) months. Tumours
frequently presented as clinically ‘benign’ lumps with frank
malignant features seen in only 42 (41%) patients (indurated
tumour, 39; facial nerve palsy, 12; including nine with both).
Cervical lymphadenopathy was uncommon at presentation (8%)
and notably was not documented in patients with adenoid cystic
carcinoma (Fisher’s exact test; P < 0.0001).
Tumours were staged retrospectively in accordance with AJCC
(Fleming et al, 1997). Histological classification was reviewed in
the mid-1970s and updated in line with the criteria of WHO
(Seifert and Sobin, 1991). Tumour types were assigned to three
grades representing different levels of biological behaviour.
Mucoepidermoid and adenocarcinoma were subclassified into
low-and high-grade based on histological features, while the
remaining tumour types were assigned as reflected by their natural
history (Table 1). This clinical grading system is similar to those
proposed by the AFIP (Ellis et al, 1991) and other major institutes
(Spiro, 1986; Kane et al, 1991).
All patients were treated surgically by two consecutive surgeons
ensuring continuity in management (late WAB Nicholson
1956–1972; ENG 1973–1992). Twenty-four (23%) underwent
local extracapsular dissection (McGurk et al, 1996), 45 (44%)
formal parotidectomy with nerve identification (superficial, 34;
total, 11) and 34 (33%) a more radical approach (partial nerve
sacrifice, 12; total nerve sacrifice, six; extended parotidectomy,
16). Radical neck dissection was performed in eight patients, all
with clinically palpable nodes.
Sixty-six (64%) patients received post-operative radiotherapy
(RT). In the early part of the series, five patients were treated (as
was routine at that time) with interstitial therapy (single plane and
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V-implants) which typically delivered 60 Gy in 7 days. Sixty-one
patients were treated with once daily megavoltage radiation
(4 MeV: 50–55 Gy: 15–16 fractions: median 21 days). The indica-
tions were: positive (12 of 16 had RT) or equivocal (28 of 34)
margins, T size > 4 cm (38 of 52), high-grade (28 of 39), adenoid
cystic histology (12 of 22) and perineural involvement (eight of
12), and many patients had more than one indication. An inclined
plane was used to avoid exit beams irradiating the eyes and the
techniques grouped as single field (three patients), wedge pair
(18 patients) and wedge three field (40 patients). The median time
to the start of radiation was 33 days post-operatively.
Statistical analysis
Survival curves were calculated by the Kaplan–Meier method.
Distributions were compared using the log-rank test and the Cox
proportional hazards regression model used to identify indepen-
dent determinants of survival. The percentages of patients with
locoregional recurrences and distant metastases were analysed as
simple proportions as the length of follow-up and ways of
censoring were similar.
RESULTS
Prognostic factors
Survival
The overall 5-, 10- and 15-year disease-specific survival rates
were 78%, 65% and 63% respectively. There were 33 cancer
deaths; 20 with distant metastases (DM) only, eight with locore-
gional recurrence (LRR) only and five with both DM and LRR.
There were no treatment-related deaths.
The factors influencing survival on univariate analysis, in order
of significance, were: tumour size (P < 0.0001), palpable cervical
nodes (P < 0.0001), histological type (P = 0.003), patient’s age
(P = 0.003), microscopic disease in para-parotid nodes
(P = 0.004), positive or close microscopic tumour margin
(P = 0.01), perineural involvement (P = 0.02), local extension with
and without facial nerve palsy (P = 0.03) and duration of
symptoms (P = 0.04).
Clinical stage (a composite of T size, local extension and nodal
status) was very predictive for survival; the 10-year disease-
specific survival rates for stage I, II and III/IV were 96%, 61% and
17% respectively (Figure 1). The 10-year survival for patients with
low-, intermediate- and high-grade cancers was 91%, 41% and
Table 1 Clinical and histological characteristics by grade
Grade
Low Intermediate High Total
(n = 41) (n = 23) (n = 39) (n = 103)
Age
Median (years) 50 60 66 59
Range (years) 9–85 31–80 26–92 9–92
< 40 years 15 1 3 19 (18)
Stage (AJCC 5th ed.)
I (T1N0M0, T2N0M0) 22 5 5 32 (31)
II (T3N0M0) 14 14 20 48 (47)
III/IV (T4N0M0, any TN1M0) 5 4 14 23 (22)
Histological type
Acinic cell ca. 9 – – 9 (9)
Mucoepidermoid ca. 22 – 1 23 (22)
Basal cell adenocarcinoma 1 – – 1
Papillary cystadenocarcinoma 4 – – 4 (4)
Mucinous adenocarcinoma 1 – – 1
Adenocarcinoma, NOS 4 – 7 11 (11)
Adenoid cystic carcinoma – 22 – 22 (21)
Epithelial-myoepithelial ca. – 1 – 1
Ca. ex-pleomorphic adenoma – – 14 14 (14)
Squamous cell carcinoma – – 5 5 (5)
Undifferentiated carcinoma – – 12 12 (12)
Values in parentheses are percentages. NOS: not otherwise specified.
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Figure 1 Survival by clinical staging
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Figure 2 Survival by tumour grade. LG = low grade; HG = high grade
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50% respectively (Figure 2). Tumour size was more important
than tumour grade, for in small tumours, the prognosis was good
for both low-and high-grade tumours (100% vs 96% at 10 years)
compared to a markedly worse outcome for high-versus low-grade
(35% vs 75% at 10 years) in larger tumours (Figure 3).
The multivariate analysis revealed that tumour size, presence of
cervical nodes, clinical grade and perineural involvement were
independent predictors for survival (Table 2).
Locoregional recurrence
The LRR rate was 25% with a median interval following initial
surgery of 30 months (range 5–168). Of the 26 patients with recur-
rence, 18 were at the primary site, nine were nodal, including one
patient who relapsed at both sites. All but one nodal metastasis
occurred on the ipsilateral side at AAOHNS neck levels I, II and
III (Robbins et al, 1991). No single factor was predictive of LRR
by univariate analysis, probably due to the confounding effect of
adjuvant RT, but multivariate analysis demonstrated that tumour
size (negatively) and adjuvant radiation (positively) were indepen-
dently important.
Distant metastasis
Twenty-five (24%) patients had clinically recognizable distant
metastases (DM). The commonest sites were: lung (n = 17), bone
(n = 6) and brain (n = 4). DM were influenced, on univariate
analysis, by tumour size (T1, 0%; T2, 5%; T3, 38%; T4, 73%;
P < 0.0001) and grade (low, 2%; intermediate, 44%; high, 36%;
P < 0.001) and, on multivariate analysis, were best predicted by
tumour size, presence of cervical nodes, local extension and grade.
Despite apparent local cure in 77 patients, 20 (26%) patients still
developed DM, suggesting that in many patients microscopic
dissemination had already occurred at presentation.
Table 2 Multivariate analyses for survival, locoregional recurrence and distant metastasis
Survival Locoregional recurrence Distant metastasis
Variable P-valuea RR 95% CI P-value RR 95% CI P-value RR 95% CI
T sizeb (³ 4 cm vs < 4 cm) < 0.001 8.17 2.4–27.5 0.01 3.09 1.3–7.3 0.005 8.49 1.9–37
Cervical node (yes vs no) 0.001 7.57 2.7–21.2 NS 0.01 4.49 1.3–15
Local extension (yes vs no) NS NS 0.02 2.87 1.1–7.2
Gradec (ADCC vs low) 0.01 7.21 1.6–33.1 NS 0.05 7.98 1.0–36
(high vs low) 0.02 6.12 1.4–27.6 NS 0.05 7.64 1.0–30
Perineural invasiond (yes vs no) 0.01 3.74 1.3–10.6 NS NS
Post-operative RT (yes vs no) NS 0.003 0.24 0.1–0.5 NS
RR, relative risk; CI, confidence interval; RT, radiotherapy; ADCC, adenoid cystic carcinoma; NS, not significant. aLikelihood ratio test using forward stepwise
method. BSeparate model: stage substituted for size, nodal status and local extension: Stage II, RR, 8.37, P = 0.04, Stage III/IV, RR, 24.1, P = 0.002. cNon-
binary variables treated as categorical to avoid contamination of the P-value caused by searching for the most informative cut-point. dBased on a model of 91
patients due to incomplete data.
Table 3 Extent of surgery and outcome
Positive/equivocal Post-operative Local 10-year
Extent of surgery margina RT failure survival (%)
All tumours
a)Nerve preservation
Local dissection 10/20 (50) 13/24 (54) 5/24 (21) 68
Formal parotidectomy 23/41 (56) 28/45 (62) 9/45 (20) 78
b)Nerve sacrifice 17/30 (57) 25/34 (74) 4/34 (12) 45b
Stage I (mobile tumours < 4 cm, n = 32)
a) Nerve preservation
Local dissection 4/9 (44) 6/12 (50) 1/12 (8) 100
Formal parotidectomy 7/18 (39) 10/19 (53) 5/19 (26) 94
b) Nerve sacrifice 1/1 1/1 0
aexact histological information on margin status was unavailable in 4 patients. bsurvival for radical surgery vs nerve preserving
surgery: 45% vs 74% at 10 years, P = 0.003.
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Treatment-related factors
Extent of surgery
Not surprisingly, survival was worse for patients undergoing
radical surgery versus nerve-preserving surgery (45% vs 74% at
10 years, P= 0.003) but the extent of surgery had no influence on
survival in a multivariate model taking T size, grade, adjuvant
radiotherapy and surgeon into consideration. Similarly, there was
no difference in outcome between the two surgeons when adjusted
for case-mix.
Subanalysis of the surgical techniques used in 32 stage I cancers
which presented as ‘clinically benign’ demonstrated no difference
in outcome between extracapsular dissection and superficial
parotidectomy (Table 3). Local failures were more frequent
following formal parotidectomy (26% vs 8%, P= 0.4), although
10-year survival rates differed little (100% vs 94%, P= 0.48)
Combined therapy versus surgery alone
For the whole group, there was no difference in survival between
combined therapy versus surgery alone (5- and 10-year survival
rates for SG+RT were 78%, 67% vs SG, 77%, 63%, P= 0.83). The
Cox analysis confirmed that survival was unaffected by post-oper-
ative RT but when outcome was subanalysed by tumour size and
grade, adjuvant RT provided some survival benefit in tumours > 4
cm (SG+RT, 63% vs SG, 33% at 5 years) (Figure 4) and high-
grade disease (SG+RT, 56% vs SG, 45% at 5 years) (Figure 5).
Adjuvant radiotherapy significantly reduced LRR (SG+RT,
15% vs SG, 43%, P= 0.002), which was confirmed in the Cox
analysis. All patient subgroups benefited from adjuvant radiation,
though this was most evident in patients with tumours > 4cm, a
histology of adenoid cystic carcinoma and high-grade disease
(Figure 6).
DISCUSSION
This study confirms that long-term survival in parotid cancer is
determined primarily by tumour characteristics, mainly clinical
stage and tumour grade (Calearo and Pastore, 1995), and that post-
operative radiation significantly improves locoregional control but
not survival (Jackson et al, 1983; Theriault and Fitzpatrick, 1986,
Spiro et al, 1989). Three additional aspects of the clinical course
and treatment of this malignancy have been identified: First, from
a treatment perspective, histological classification can be simpli-
fied into three categories; second, a conservative surgical approach
to small apparently ‘benign’ parotid cancers does not compromise
local control and survival; and third, post-operative radiation may
offer some survival advantage in large and high-grade tumours.
In terms of prognosis, tumour size was the most important vari-
able for no cancer deaths occurred among patients with tumours <
2cm, but all patients with tumours > 6cm died of disease. Nodal
metastasis was an uncommon event but when present it was an
important adverse prognostic factor (Spiro et al, 1993). Facial
nerve palsy is another poor prognostic sign, though it did not indi-
cate incurable disease as six of 12 patients experienced long-term
disease-free survival. In contradiction to other reports
(Frankenthaler et al, 1991; Poulson et al, 1992), age was not an
independent predictor of survival, though notably, young patients
tended to have low-grade tumours (79%) and there were no
cancer-related deaths in patients under 40 years.
Based on survival analysis, the various different histological
types segregated into three clinical patterns; low-grade (indolent),
intermediate grade and high-grade (aggressive) tumours. The
natural history of low-grade cancers (acinic cell, low-grade
mucoepidermoid, papillary cystadenocarcinoma, basal cell adeno-
carcinoma) is for long-term disease-free survival, while high-
grade cancers (carcinoma ex-pleomorphic adenoma, high-grade
mucoepidermoid, squamous cell, undifferentiated) behave more
like squamous cell carcinomas of the upper aerodigestive tract.
Intermediate grade cancers (predominantly adenoid cystic carci-
noma) show a pattern of progressive failure through distant metas-
tases. The latter observation supports Spiro’s assertion (Spiro et al,
1989) that subclassification of adenoid cystic carcinoma into
histomorphological patterns (solid, trabular, cribiform) probably
matters little to long-term survival.
The influence of surgical procedure on outcome was difficult to
disentangle from confounding factors such as adjuvant radio-
therapy though the extent of surgery did not effect outcome in
either the univariate or multivariate analysis. The failure to iden-
tify a difference may have resulted as the treatment selected was
appropriate for the individual tumour. Contrary to expectations,
extracapsular dissection did not effect outcome in Stage I tumours,
Figure 5Comparison of survival in patients treated with surgery alone
versus combined therapy according to tumour grade. LG, low-grade; HG,
high-grade; SG, surgery alone: SG+RT, surgery with adjuvant radiation.
Numbers in lower half of graph are number of patients per group at time zero
Figure 6Comparison of locoregional recurrence rates in patients treated by
surgery alone versus combined therapy considered by tumour size and
tumour grade. Numbers below horizontal line are number of patients per
group. ADCC denotes adenoid cuptic
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the inference being that small mobile parotid cancers do not
require wide resection (Leverstein et al, 1998). This in practice is
the approach adopted by most surgeons since these tumours
present as clinically benign lumps and are treated as such (McGurk
et al, 1995).
In general, survival from parotid cancer was unaffected by post-
operative RT, a conclusion also reached by others (Spiro et al, 1989).
Accepting some unfavourable selection bias in patients receiving
combined therapy, the expectation was for a worse outcome in these
patients. However, this was not the case but rather a modest (and
probably real) survival benefit was identified with adjuvant RT in
patients with tumours > 4 cm. This confirms similar observations
made by Armstrong et al (1990), and mirrors the survival benefits of
adjuvant RT seen in patients with high-risk breast cancer (Overgaard
et al, 1997). The influence on survival of adjuvant RT in high-grade
tumours is more complex as smaller survival advantages were seen
in this series and others (Armstrong et al, 1990; Frankenthaler et al,
1991). Some of the beneficial effect of adjuvant therapy may simply
reflect tumour size as small, high-grade tumours had a good prog-
nosis (96% at 5 years) (Spiro and Huvos, 1992).
The overall incidence of DM (24%) was similar to that reported
elsewhere and best predicted by tumour size, local extension, nodal
status and grade (Gallo et al, 1997). This was unaffected by post-
operative RT reaffirming improvement in locoregional control
remains its main role in the treatment of parotid cancer (Sykes et al,
1995). Some 80% of DM occurred despite locoregional control,
which suggests both early dissemination of disease and the need to
develop new effective systemic treatment strategies.
The current histological classification of salivary gland cancer
has over-influenced thinking on the treatment of salivary tumours
(McGurk et al, 1995). The present results emphasize the impor-
tance of clinical factors rather than histology in determining treat-
ment results.
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